首頁(yè)
訂購(gòu)/客服:400-666-5481

PD0332991 HCl

    
99%

PD0332991 HCl

源葉(MedMol)
S80973 一鍵復(fù)制產(chǎn)品信息
827022-32-2
C24H29N7O2·HCl
483.99
6-乙酰基-8-環(huán)戊基-5-甲基-2-[[5-(1-哌嗪基)-2-吡啶基]氨基]吡啶并[2,3-d]嘧啶-7(8H)-酮鹽酸鹽
貨號(hào) 規(guī)格 價(jià)格 上海 北京 武漢 南京 購(gòu)買數(shù)量
S80973-5mg 99% ¥200.00 >10 - - -
S80973-10mg 99% ¥350.00 >10 - - -
S80973-25mg 99% ¥500.00 >10 - - -
S80973-100mg 99% ¥1200.00 >10 - - -
產(chǎn)品介紹 參考文獻(xiàn) 質(zhì)檢證書(shū)(COA) 摩爾濃度計(jì)算器 相關(guān)產(chǎn)品

產(chǎn)品介紹

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma

產(chǎn)品描述: Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma
靶點(diǎn): Cdk4/cyclin D3:9 nM (IC50);Cdk4/cyclin D1:11 nM (IC50);Cdk6/cyclin D2:16 nM (IC50);DYRK1A:2000 nM (IC50);MAPK:8000 nM (IC50);CDK
體內(nèi)研究: Palbociclib monohydrochloride (oral adminstration, 75 or 150 mg/kg, daily for 14 days) produces rapid tumor regressions and delays tumor growth. Palbociclib monohydrochloride (oral adminstration, 90 mg/kg, daily for 12 days) reduces Treg numbers and the Treg:CD8 ratio in the spleen and lymph nodes in tumor-free mice, demonstrating the tumor-independent effects. Palbociclib monohydrochloride (oral administration, 100 mg/kg, daily for 1 week) has potent antitumour effects in genetically engineered mosaic mouse model of liver cancer
參考文獻(xiàn): 1. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. 2. Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475. 3. Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. 4. Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66(7):1286-1296.
溶解性: Soluble  in  DMSO、H2O
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.066 ml 10.331 ml 20.662 ml
5 mM 0.413 ml 2.066 ml 4.132 ml
10 mM 0.207 ml 1.033 ml 2.066 ml
50 mM 0.041 ml 0.207 ml 0.413 ml
注意: 部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。

參考文獻(xiàn)

質(zhì)檢證書(shū)(COA)

如何獲取質(zhì)檢證書(shū)(COA)?
請(qǐng)輸入貨號(hào)和一個(gè)與之匹配的批號(hào)。
例如:
批號(hào):JS298415 貨號(hào):S20001-25g
在貨品標(biāo)簽上如何找到貨號(hào)和批號(hào)?

摩爾濃度計(jì)算器

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關(guān)產(chǎn)品